214 related articles for article (PubMed ID: 19806487)
21. Outpatient pharmacy care and HIV viral load response among patients on HAART.
Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner JS; Hogg RS
AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
[TBL] [Abstract][Full Text] [Related]
22. Awareness and attitude of health workers at a Nigerian HIV treatment clinic toward HIV/AIDS and HAART adherence.
Olowookere SA; Fatiregun AA; Osagbemi KG
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):208-12. PubMed ID: 19357425
[TBL] [Abstract][Full Text] [Related]
23. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
[TBL] [Abstract][Full Text] [Related]
24. Three types of adherence to HIV antiretroviral therapy and their association with AIDS diagnosis, medication side-effects, beliefs about antiretroviral therapy, and beliefs about HIV disease.
Schönnesson LN; Williams ML; Ross MW; Diamond PM; Keel B
Int J STD AIDS; 2007 Jun; 18(6):369-73. PubMed ID: 17609023
[TBL] [Abstract][Full Text] [Related]
25. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
Tyndall MW; McNally M; Lai C; Zhang R; Wood E; Kerr T; Montaner JG
Int J Drug Policy; 2007 Aug; 18(4):281-7. PubMed ID: 17689376
[TBL] [Abstract][Full Text] [Related]
26. HIV patient insight on adhering to medication: a qualitative analysis.
Beusterien KM; Davis EA; Flood R; Howard K; Jordan J
AIDS Care; 2008 Feb; 20(2):244-52. PubMed ID: 18293136
[TBL] [Abstract][Full Text] [Related]
27. Stigma and social barriers to medication adherence with urban youth living with HIV.
Rao D; Kekwaletswe TC; Hosek S; Martinez J; Rodriguez F
AIDS Care; 2007 Jan; 19(1):28-33. PubMed ID: 17129855
[TBL] [Abstract][Full Text] [Related]
28. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women.
Cook JA; Grey D; Burke-Miller J; Cohen MH; Anastos K; Gandhi M; Richardson J; Wilson T; Young M
AIDS Care; 2006 Feb; 18(2):93-100. PubMed ID: 16338766
[TBL] [Abstract][Full Text] [Related]
29. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs.
Ware NC; Wyatt MA; Tugenberg T
Soc Sci Med; 2005 Aug; 61(3):565-76. PubMed ID: 15899316
[TBL] [Abstract][Full Text] [Related]
30. An exploration of factors influencing adherence to highly active anti-retroviral therapy (HAART) among people living with HIV/AIDS in Northern Thailand.
Ruanjahn G; Roberts D; Monterosso L
AIDS Care; 2010 Dec; 22(12):1555-61. PubMed ID: 20582752
[TBL] [Abstract][Full Text] [Related]
31. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
Palepu A; Tyndall MW; Li K; Yip B; O'Shaughnessy MV; Schechter MT; Montaner JS; Hogg RS
J Urban Health; 2003 Dec; 80(4):667-75. PubMed ID: 14709714
[TBL] [Abstract][Full Text] [Related]
32. Patients' perception of information about HAART: impact on treatment decisions.
Gellaitry G; Cooper V; Davis C; Fisher M; Date HL; Horne R
AIDS Care; 2005 Apr; 17(3):367-76. PubMed ID: 15832885
[TBL] [Abstract][Full Text] [Related]
33. Which factors hinder the decision of Polish HIV-positive patients to take up antiretroviral therapy?
Rogowska-Szadkowska D; Chlabicz S; Oltarzewska MA; Sawicka-Powierza J
AIDS Care; 2009 Mar; 21(3):280-3. PubMed ID: 19280405
[TBL] [Abstract][Full Text] [Related]
34. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.
Lambers FA; Stolte IG; van den Berg CH; Coutinho RA; Prins M
Int J Drug Policy; 2011 May; 22(3):210-8. PubMed ID: 21392958
[TBL] [Abstract][Full Text] [Related]
35. Use of antiretroviral therapy among HIV positive individuals living in British Columbia.
Rusch M; Nixon S; Schilder A; Braitstein P; Chan K; Hogg RS
AIDS Care; 2004 Oct; 16(7):914-22. PubMed ID: 15385247
[TBL] [Abstract][Full Text] [Related]
36. Social and structural determinants of HAART access and adherence among injection drug users.
Krüsi A; Wood E; Montaner J; Kerr T
Int J Drug Policy; 2010 Jan; 21(1):4-9. PubMed ID: 19747811
[TBL] [Abstract][Full Text] [Related]
37. Medication adherence for HIV positive women caring for children: in their own words.
Wood SA; Tobias C; McCree J
AIDS Care; 2004 Oct; 16(7):909-13. PubMed ID: 15385246
[TBL] [Abstract][Full Text] [Related]
38. Active injection drug-abuse offsets healthcare engagement in HIV-infected patients.
Liappis AP; Laake AM; Delman M
AIDS Behav; 2015 Jan; 19(1):81-4. PubMed ID: 24710959
[TBL] [Abstract][Full Text] [Related]
39. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.
Clarke S; Delamere S; McCullough L; Hopkins S; Bergin C; Mulcahy F
HIV Med; 2003 Jan; 4(1):33-7. PubMed ID: 12534957
[TBL] [Abstract][Full Text] [Related]
40. Injection drug use, HIV/AIDS and incarceration: evidence from the Vancouver Injection Drug Users Study.
Small W; Wood E; Jürgens R; Kerr T
HIV AIDS Policy Law Rev; 2005 Dec; 10(3):1, 5-10. PubMed ID: 16544394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
